

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

May 31, 2017

Mr. Thomas E. Klema Secretary Rockwell Medical, Inc. 30142 Wixom Road Wixom, Michigan 48393

Re: Rockwell Medical, Inc.

Additional Soliciting Materials on Schedule 14A

Filed May 26, 2017 File No. 000-23661

Dear Mr. Klema:

We have reviewed your filing and have the following comments.

General

1. We note the following disclosure: "Richmond and Ravich have ... [t]hreatened to gain control of Rockwell (without paying a premium to Rockwell shareholders)." Please qualify any such statement in the future by noting that control premiums are not commonly associated with exercising a right to nominate directors, but rather with purchases of a controlling interest in the capital stock of a company.

You may contact me at (202) 551-3503 if you have any questions.

Sincerely,

/s/ David L. Orlic

David L. Orlic Special Counsel Office of Mergers and Acquisitions

cc: Peter D. Fetzer, Esq. Foley & Lardner LLP